Common Contracts
4 similar Advisory Board Agreement contracts
Advisory Board Agreement between a patient advocate and a pharmaceutical companyAdvisory Board Agreement • November 18th, 2021
This is a reference agreement, specific for advisory board engagements, that should be adapted according to the needs of the users. It is based on the “Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies”, provided by the WECAN project on “Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies”, For the most recent version and more information about the guiding principles, please visit www.wecanadvocate.eu/rapp
Advisory Board Agreement between a patient advocate and a pharmaceutical companyAdvisory Board Agreement • June 18th, 2020
Reference agreement “Advisory Boards” version 1.3 (16 June 2020) This is a reference agreement, specific for advisory board engagements, that should be adapted according to the needs of the users. It is based on the “Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies”, provided by the WECAN project on “Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies”, For the most recent version and more information about the guiding principles, please visit www.wecanadvocate.eu/rapp
Advisory Board Agreement between a patient advocate and a pharmaceutical companyAdvisory Board Agreement • December 17th, 2019
Reference agreement “Advisory Boards” version 1.2 (1 December 2019) This is a reference agreement, specific for advisory board engagements, that should be adapted according to the needs of the users. It is based on the “Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies”, provided by the WECAN project on “Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies”, For the most recent version and more information about the guiding principles, please visit www.wecanadvocate.eu/rapp
Advisory Board Agreement between a patient advocate and a pharmaceutical companyAdvisory Board Agreement • December 17th, 2019
Reference agreement “Advisory Boards” version 1.2 (17 December 2019) This is a reference agreement, specific for advisory board engagements, that should be adapted according to the needs of the users. It is based on the “Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies”, provided by the WECAN project on “Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies”, For the most recent version and more information about the guiding principles, please visit www.wecanadvocate.eu/rapp
